about
Targeted gene disruption to cure HIVPredictors of hepatitis B cure using gene therapy to deliver DNA cleavage enzymes: a mathematical modeling approachIn vivo dynamics of AAV-mediated gene delivery to sensory neurons of the trigeminal gangliaEvaluation of adenovirus vectors containing serotype 35 fibers for vaccinationGenome editing and the next generation of antiviral therapy.In vivo disruption of latent HSV by designer endonuclease therapyAAV-mediated delivery of zinc finger nucleases targeting hepatitis B virus inhibits active replicationNovel viral vector systems for gene therapy.Detection of treatment-resistant infectious HIV after genome-directed antiviral endonuclease therapy.Digital detection of endonuclease mediated gene disruption in the HIV provirus.Development of group B adenoviruses as gene transfer vectors.DNA cleavage enzymes for treatment of persistent viral infections: recent advances and the pathway forward.In Vivo Hematopoietic Stem Cell Transduction.Tuning DNA binding affinity and cleavage specificity of an engineered gene-targeting nuclease via surface display, flow cytometry and cellular analyses.Biodistribution and safety profile of recombinant adeno-associated virus serotype 6 vectors following intravenous delivery.A new group B adenovirus receptor is expressed at high levels on human stem and tumor cells.Pharmacodynamics of anti-HIV gene therapy using viral vectors and targeted endonucleases.TALENs targeting HBV: designer endonuclease therapies for viral infections.Adenovirus expression of IL-1 and NF-kappaB inhibitors does not inhibit acute adenoviral-induced brain inflammation, but delays immune system-mediated elimination of transgene expression.Towards global and long-term neurological gene therapy: unexpected transgene dependent, high-level, and widespread distribution of HSV-1 thymidine kinase throughout the CNS.CRISPR/Cas9 and Genome Editing for Viral Disease-Is Resistance Futile?Viral diversity is an obligate consideration in CRISPR/Cas9 designs for targeting the HIV reservoir.Gene transfer into rat brain using adenoviral vectorsThe complete nucleotide sequence, genome organization, and origin of human adenovirus type 11
P50
Q27023171-38C7E0D9-7DD8-4341-BBC0-AA7CDC447D95Q27324340-A50A89EA-0538-412A-B1A5-04997110E0F4Q33680976-5ECF8338-64F2-4FAB-B550-2DB27077C18EQ34507185-279D7124-E881-406E-BFEA-FCD1802DAF28Q34529971-499FC98D-BBBA-4A54-A3F7-6E6F9D42ACA9Q34540648-B7F6425E-DB2B-4B63-B8A1-D921D65E2267Q35168444-948FB239-63FC-4753-A7E6-91BA5BB37C33Q35260938-8C106FA0-DBF2-4294-AA49-02060760CBE1Q36494284-339F55C0-4DBB-45E7-80CE-A3A43D5D7637Q36528328-05BB3B83-6F4B-49C3-8C8D-137ACBE9635CQ37162316-9F94C633-34EA-4A1C-9E00-F63ED39D99D7Q38184158-5764C88A-2B57-49DE-8DF4-44D3EAB0033EQ40045829-37721542-499A-4CED-B7DF-CBBF322D519DQ40057209-2628C936-318E-4997-9FCD-572C7D28AC56Q40091715-1E8B6CE7-FBDF-4000-9E68-E6CA9E93E5C6Q40223632-400D6907-7843-45FF-B128-EB214BD9F4DEQ40709550-B6C4E487-4C57-4096-BE3C-4DCFA14C3B55Q42245971-C8C18B27-0C71-402F-B091-7CA6E2ACAFE6Q42613158-41B7BDAD-09C5-4522-85B2-5661218ECBBDQ43799589-C34A0336-2295-458D-9BA3-D905341BDC71Q52430698-2763EA62-D517-4AC5-95DE-28253496E36DQ55654521-1CB75816-40B4-43B4-B5FD-CED67B564F98Q64376692-EA2E3972-E638-42B9-B0C1-98D0C3609578Q64377759-60CD16B3-9BAD-4E02-9795-C59CB537F1A3
P50
description
researcher ORCID ID = 0000-0003-1619-7541
@en
wetenschapper
@nl
name
Daniel Stone
@ast
Daniel Stone
@en
Daniel Stone
@es
Daniel Stone
@nl
type
label
Daniel Stone
@ast
Daniel Stone
@en
Daniel Stone
@es
Daniel Stone
@nl
prefLabel
Daniel Stone
@ast
Daniel Stone
@en
Daniel Stone
@es
Daniel Stone
@nl
P108
P108
P21
P31
P496
0000-0003-1619-7541